Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 129
Selected: 0
NCT IDTitle
NCT01681433OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
NCT04289779Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer
NCT07218666Zanzalintinib in Men With Aggressive Variant Prostate Cancer
NCT00417248Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
NCT02365766Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
NCT01736917Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
NCT04069273Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
NCT04541173Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
NCT03272217Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
NCT03547999A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
NCT04886531Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT03317158Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT06493019Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
NCT05498272Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
NCT01071928Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
NCT06863311Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
NCT00730353Sutent + Taxol for Advanced Esophageal Cancer
NCT02500901Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)
NCT03557918Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
NCT04470674Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
NCT03476174Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
NCT05928806Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
NCT04610684Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
NCT00317200A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer
NCT06855225A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
NCT00216099Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer
NCT03041181Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
NCT02375672Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
NCT04711824Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT00632541A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
NCT03501381High Dose IL 2 and Entinostat in RCC
NCT03971409Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
NCT00706641Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder
NCT03502746Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
NCT05442216Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
NCT04849364Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
NCT00216073Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer
NCT00216203Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
NCT00216021Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
NCT02101385Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
NCT03396471Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary
NCT02582749Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
NCT03909334Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT03099564Pembrolizumab Plus Y90 Radioembolization in HCC Subjects
NCT04589832Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
NCT01732107Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression
NCT02549209Pembro/Carbo/Taxol in Endometrial Cancer
NCT01232881Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer
NCT05251038Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer